EPO Rules AstraZeneca MUPS® Patent Valid
The European Patent Office (EPO) Opposition Division today ruled that the European patent for a MUPS® formulation (EP 723 437) is still valid in amended form, despite four oppositions from generic drug manufacturers.
This positive decision means that this patent covering a multiple unit tablet is still valid in Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, UK, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, The Netherlands, Portugal, Sweden, Latvia, Lithuania and Slovenia until 2015.
MUPS® stands for multiple unit pellet tablets, comprising a proton pump inhibitor (PPI) compound. The formulation is used for Nexium® and Losec® tablets and the amended claims still cover these products.
AstraZeneca has a comprehensive intellectual property portfolio protecting MUPS® formulations as well as the products Nexium® and Losec®. More importantly, the intellectual property portfolio protecting Nexium® includes additional patents with expiration dates ranging from 2009 through to 2018. In addition to these patents, Nexium® has data exclusivity valid until March 2010 in most major European markets.
Media Enquiries:
Edel McCaffrey, +44 207 304 5034 (24 hours)
WebWireID53068
- Contact Information
- Steve Brown
- Media Enquiries
- AstraZeneca
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.